CLIA Chromogranin A
The prevalence of neuroendocrine tumors (NETs) in Europe is approximately 3 cases per 100,000 inhabitants and has been steadily increasing in recent years. NETs are a rare but clinically significant group of tumors arising from the uncontrolled proliferation of neuroendocrine cells. They most commonly occur in the gastrointestinal tract, lungs, pancreas, and kidneys. These tumors are classified into functional types, which produce excess biologically active hormones causing specific symptoms, and non-functional types, which do secrete hormones, but in amounts insufficient to cause clinical manifestations.
Chromogranin A (CgA) is a key biomarker for the diagnosis and monitoring of NETs, enabling earlier detection due to its elevated levels in most NET subtypes.
Produkt
| Product | Size | Article no. | |
|---|---|---|---|
|
100 Tests
|
Article no.: 71072 | Request |
Advantages
- CgA is present in all types of neuroendocrine cells, making it broadly applicable across different NET types
- Suitable for monitoring disease progression – CgA levels often correlate with tumor burden and may reflect treatment response.
- Offers the advantage of simple and non-invasive determination from a blood sample
- The kits are CE-IVD certified and intended for professional use
- For each CLIA kit a corresponding control set is available
| Assay Time | 20 min |
| Assay stability | 30 days on-board-stability / in-use-stability until the expiration date at storage temperature 2-8 °C |
| Sample Matrix | Serum, Plasma |
| Sample volume | 10 µL |
| Measuring range | 0 - 2000 ng/ml |
| Assay/kit content | Reagent Cartridge with specific reagents for the assay, magnetic particles, calibrators |